Exporter

You can select particular sections to be included in the output file.
EN
FR

Liste modèle des médicaments essentiels

effacer Trouvé 28 recommandations pour 21 médicaments et 9 équivalents thérapeutiques
Les recommandations supprimées et les demandes rejetées sont affichées. Les cacher.
8.2.2. Targeted therapies
  1. Abemaciclib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast
  2. Afatinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung
  3. All-trans retinoic acid Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  4. Axitinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid > tablet: 1 mg; 3 mg; 5 mg
    Indications
    Renal cell carcinoma of kidney, except renal pelvis
  5. Binimetinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib pour Other specified melanoma of skin
  6. Bortezomib Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  7. Cobimetinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib pour Other specified melanoma of skin
  8. Crizotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 200 mg; 250 mg
    • Oral > Solid > capsule: 200 mg; 250 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Anaplastic large cell lymphoma, ALK-positive
  9. Dabrafenib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 50 mg; 75 mg
    Indications
    Other specified melanoma of skin
  10. Dasatinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  11. Encorafenib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin
  12. Erlotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  13. Everolimus Informations générales
    Section
    Targeted therapies
    • Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
    • Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
    Indications
    Other specified gliomas of brain
  14. Gefitinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung
  15. Ibrutinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  17. Lenvatinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid > capsule: 4 mg; 10 mg
    Indications
    Renal cell carcinoma of kidney, except renal pelvis
  18. Nilotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid > capsule: 150 mg; 200 mg
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  19. Osimertinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)
    Indications
    Other specified malignant neoplasms of bronchus or lung
  20. Palbociclib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 75 mg; 100 mg; 125 mg
    Indications
    Other specified malignant neoplasms of breast
  21. Panitumumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial
    Indications
    Other specified malignant neoplasms of large intestine
  22. Pertuzumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution
    Indications
    Carcinoma of breast, specialised type
  23. Ribociclib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast
  24. Rituximab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphoma, not otherwise specified
  25. Trametinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 0.5 mg; 2 mg
    Indications
    Other specified melanoma of skin
  26. Trastuzumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  27. Trastuzumab emtansine Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  28. Vemurafenib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin
  29. Zanubrutinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 80 mg
    • Oral > Solid > capsule: 80 mg
    Indications
    Mantle cell lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to ibrutinib pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma